AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04969328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ParTNer-STEPs
Description: The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~1. an informative website available for parents from recruitment until follow-up.~2. online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~3. transfer consultations across the paediatric and adult department. The transition consultations consist of:~   * a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~  * a farewell consultation with the paediatric nurse (0-3 months before transfer).~  * a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~  * a welcoming consultation with the nurse from the adult care (0-3 months after transfer).
Study NCT05535517 — intervention group
Intervention type: OTHER
Intervention: CeraVe SA Smoothing Cream
Description: The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
Study NCT05535517 — intervention group
Intervention type: OTHER
Intervention: Propaira 20% Lactic Acid Exfoliating Lotion
Description: For smoothing rough skin.
Study NCT05535517 — intervention group
Intervention type: OTHER
Intervention: Propaira 30% Urea Exfoliating Emollient
Description: 30% Urea, 7% Glycerin to smoothen rough skin.
Study NCT05535517 — intervention group
Intervention type: OTHER
Intervention: KPAI
Description: The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
Study NCT05535517 — intervention group
Intervention type: OTHER
Intervention: KP-IGA
Description: A standard 5-point IGA score (0-4) defined specifically for KP
Study NCT05809869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
Study NCT05809869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 300mg intravenous infusion on week 1 only.
Study NCT05809869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolisation
Description: Yttrium-90 radioembolisation on week 2 only.
Study NCT06217705 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project Calm
Description: Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
Study NCT06217705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Calm
Description: Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
Study NCT05478005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
Study NCT04853082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limonene capsule
Description: All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
Study NCT04853082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Limonene capsules(Placebo)
Description: Limonene capsules(Placebo)
Study NCT05733169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency lowering intervention
Description: Modified parametrization of the current frequency lowering parametrization.
Study NCT05733169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency lowering reference
Description: Current frequency lowering parametrization
Study NCT05478005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular block
Description: Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
Study NCT04656951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
Study NCT06223828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 10mg/kg/dose (max dose 500mg) once daily for 3 days
Study NCT05015881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Description: Drink a single dose of ketone ester 1.9 kcal/kg
Study NCT05015881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FDG
Description: Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
Study NCT05015881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDG
Description: Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
Study NCT06180811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Women's Health Delaware Food Farmacy
Description: Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
Study NCT06180811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standard of Care
Description: Participants will receive the usual standard of care.
Study NCT05948293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine learning model called IDoser
Description: Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
Study NCT05948293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical practice
Description: Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
Study NCT05868343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-based Cardiac Rehabilitation Intervention
Description: The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
Study NCT05868343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation Intervention
Description: The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
Study NCT05192382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, tablets, once daily by mouth
Study NCT05192382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth
Study NCT06279416 — intervention group
Intervention type: PROCEDURE
Intervention: fiberoptic intubation
Description: awake nasal fiberoptic intubation
Study NCT06279416 — intervention group
Intervention type: PROCEDURE
Intervention: laryngeal mask airway-mediated aintree catheter
Description: awake intubation with laryngeal mask airway-mediated aintree catheter
Study NCT06279416 — intervention group
Intervention type: PROCEDURE
Intervention: videolaryngoscopy
Description: awake intubation with videolaryngoscopy
Study NCT05485428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 12-weeks of high intensity interval exercise, 30 minutes thrice weekly
Study NCT06526897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06526897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography
Description: Undergo chest CT
Study NCT06526897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo CXR
Study NCT06526897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06526897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05557578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GEMOX (GOT) regimen
Description: Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
Study NCT04922398 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
Study NCT04922398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline will be injected in each ovary
Study NCT06395597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: 3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
Study NCT06059196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARCHES (Addressing Reproductive Coercion in Health Settings)
Description: ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
Study NCT06270030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study NCT06270030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNZ100 (Aceclidine) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study NCT06270030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study NCT04948307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXD01 digital therapy
Description: OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
Study NCT04948307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
Study NCT04948307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
Study NCT05704218 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: the patient will have a blood sample in order to perform serology tests
Study NCT05256732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 fasted
Description: AT-527 administered twice daily (BID) for 5 days fasted
Study NCT05256732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator fasted
Description: Matching placebo administered twice daily (BID) for 5 days fasted
Study NCT06059196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCS+ (Balanced Counseling Strategy Plus)
Description: BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
Study NCT05256732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 fed
Description: AT-527 administered twice daily (BID) for 5 days fed
Study NCT05256732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator fed
Description: Matching placebo administered twice daily (BID) for 5 days fed
Study NCT05256732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: AT-527 administered twice daily (BID)
Study NCT05256732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 single dose
Description: AT-527 single dose fasted/fed cross-over
Study NCT06059196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCS+ (Balanced Counseling Strategy Plus)
Description: BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
Study NCT04979442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAIN-32
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Study NCT04979442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: 1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
Study NCT06324214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urolithin A (Mitopure)
Description: Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
Study NCT06324214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study NCT05767255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec + liraglutide
Description: The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
Study NCT04855760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet
Study NCT06424613 — intervention group
Intervention type: DRUG
Intervention: Lithium Carbonate
Description: Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.
Study NCT06424613 — intervention group
Intervention type: DRUG
Intervention: Non-lithium medication
Description: No history of lithium use within the past year
Study NCT05040425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zi-Yin-Liang-Ge-San
Description: Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
Study NCT05774561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arm A - Diagnostic test: HPV detection in liquid biopsies
Description: Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
Study NCT05774561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arm B - Diagnostic test: HPV detection in liquid biopsies
Description: Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
Study NCT03277495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral counseling
Description: Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
Study NCT04647526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Lu-177]-PNT2002
Description: Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
Study NCT04647526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
Study NCT04647526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide (160 mg orally qd)
Study NCT05767255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine - Insulin Aspart
Description: The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
Study NCT05043649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camsirubicin
Description: The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
Study NCT04837365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three dimensional gait analysis with eyetracking
Description: An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.